Viatris plans across-the-board cuts that could endanger 9,000 workers, 15 plants in post-merger restructuring scheme
In the high-volume generics game, size matters — and no one is quite so big as new giant on the block Viatris, which launched last month. But size can also mean redundancy, and now Viatris is plotting a major restructuring to streamline its operations and bottom line.
Just weeks after merging two generics giants in Mylan and Pfizer’s Upjohn unit, newco Viatris is gearing up for wide-ranging cutbacks that could eliminate 20% of the combined firms’ global workforce and shutter or sell off a clutch of manufacturing facilities around the world, according to updated plans Viatris unveiled Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.